BMS Stands Firm on Mergers

Bristol Myers Squibb (BMS) moves forward with its plans. The company's CEO, Christopher Boerner, states that BMS feels no pressure to make big deals. Many other drug companies are buying up smaller firms. But BMS chooses a different path.

BMS closed a major deal this past December. It bought Karuna Therapeutics for $14 billion. It also acquired RayzeBio for $4.1 billion. These moves show a clear strategy. The company focuses on specific growth areas. These include cancer, immunology, and neuroscience.

Boerner highlights the company's strong project pipeline. BMS has many new drugs in development. These projects can drive future growth. The company believes in its own research. It does not need to chase other companies.

Investors should watch BMS's internal projects. The company plans to launch new products. These could bring significant returns. BMS trusts its current strategy. It builds value from within. This approach aims for steady, long-term growth.

Source: FierceBiotech